Burgdorf - Ypsomed today has to issue an ad-hoc information due to lower than expected orders for insulin pen systems. Therefore sales and profitability for the business year 2006/07 will be lower than forecasted so far. At the same time Ypsomed announced the change of the CEO. The board of directors of Ypsomed has decided to nominate as of today Richard Fritschi, former president Europe & Australasia of Zimmer/Centerpulse, as the new CEO of the Ypsomed group.
Press Releases Ypsomed Group